Neuroendocrine Tumors Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024

DelveInsight's, "Neuroendocrine Tumors Pipeline Insight 2024" report provides comprehensive insights about 115+ companies and 130+ pipeline drugs in Neuroendocrine Tumors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Neuroendocrine Tumors therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Neuroendocrine Tumors Pipeline. Dive into DelveInsight's comprehensive report today! @ Neuroendocrine Tumors Pipeline Outlook- https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Neuroendocrine Tumors Pipeline Report
• In August 2024:- Novartis Pharmaceuticals- The purpose of this study is to evaluate the diagnostic performance of [68Ga]Ga-DOTA-TATE Positron Emission Tomography (PET)/Computerized Tomography (CT) imaging compared with conventional imaging (CIM) as standard of truth in patients with neuroendocrine neoplasms (NENs) and healthy volunteers (HVs). The data from this study will provide the evidence for diagnosis of [68Ga]Ga-DOTA-TATE PET/CT imaging in patient with NENs in Japan.
• July 2024:- Georgiamune Inc- A Phase 1/2, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of GIM-531 as a Single Agent and in Combination With Anti-PD-1 in Advanced Solid Tumors. GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary effect through selective inhibition of regulatory T-cells (Tregs).
• July 2024:- UNICANCER- Dostarlimab as First-line Treatment for Patients With dMMR/MSI (Non-colorectal/Non-endometrial) Locally Advanced or Metastatic Cancer: a Randomized Phase 2 Trial (Cohort Pan-MSI ACSE) With Crossover in the Standard Arm at Progression.
• July 2024:- Merck Sharp & Dohme LLC- A Phase I/II Study of Pembrolizumab (MK-3475) in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051). Pembrolizumab is an immunotherapy, which is a treatment that helps the immune system fight cancer. Researchers want to learn if different doses of pembrolizumab can cause at least 1 of the types of cancer to get smaller or go away.
• DelveInsight's Neuroendocrine Tumors Pipeline analysis depicts a robust space with 115+ active players working to develop 130+ pipeline treatment therapies.
• The leading Neuroendocrine Tumors Companies such as Amgen, Eli Lilly and Company, GlaxoSmithKline, Hutchison Medipharma Limited, Ipsen, Seneca Therapeutics, Crinetics Pharmaceuticals, ADC Therapeutics, BeiGene, Camurus, EpicentRx, RayzeBio, Inc., Shenzhen Chipscreen Biosciences Co., Ltd., Vyriad, Inc. and others.
• Promising Neuroendocrine Tumors Therapies such as Ipilimumab, Nivolumab, Pembrolizumab, Niraparib, Apalutamide, Selpercatinib, Cabozantinib, Vandetanib, and others.

Stay ahead with the most recent pipeline outlook for Neuroendocrine Tumors. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Neuroendocrine Tumors Approved Drugs- https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Neuroendocrine Tumors Emerging Drugs
• RYZ101: RayzeBio, Inc.
RYZ101 is an investigational, targeted RPT designed to deliver a highly potent alpha-emitting radioisotope, Actinium-225 (Ac225), to solid tumors expressing SSTR2. RYZ101 leverages DOTATATE, a known binder and linker used in other radiopharmaceutical produts. RYZ101 uses Ac225 instead of the Lu177 used in Lutathera and thus delivers hundreds of times more potency in cancer cell killing. The higher potency of RYZ101 can provide significant clinical benefit to patients. RYZ101 utilizes a proprietary and patent protected formulation. The drug is being developed for gastroenteropancreatic neuroendocrine tumor, pancreatic net, neuroendocrine tumors, extensive stage small cell lung cancer (ES-SCLC), and other tumors.
• SVV-001: Seneca Therapeutics
SVV-001, an oncolytic virus of the genus Seneca in the Picornaviridae family. SVV-001 is characterized by its ability to replicate selectively in certain human tumor cells ("SVV-permissive cells"), namely those that express TEM8, the receptor of SVV. SVV-001 is non-pathogenic in humans and animals. SVV-001 and the Seneca genus was originally discovered in 2001 at Novartis Pharmaceuticals by Dr. Paul Hallenbeck. SVV-001 was further developed as a novel cancer therapeutic at Neotropix, Inc. SVV-001 has been extensively tested in over 30 non-clinical cancer models, including immunotherapeutic settings, and in three clinical trials for various solid cancer namely neuroendocrine tumors such as carcinoids, small cell lung cancer and a variety of pediatric cancers. These trials confirmed the safety of intravenous dosing of SVV-001 and safety along with suggestions of significant clinical benefit. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Neuroendocrine Tumors.
• Voyager-V1: Vyriad, Inc.
VSV-IFNβ-NIS (Voyager V1; VV1) is derived from VSV, a bullet-shaped, negative-sense RNA virus with low human seroprevalence; it is engineered to replicate selectively in and kill human cancer cells. VV1 encodes hIFNβ to increase antitumoral immune response and tumor specificity, plus the thyroidal sodium iodide symporter NIS to allow imaging of virus. VV1 is synergistic with different anti-PD-(L)1 antibodies in several tumor models. Currently the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Neuroendocrine Tumors.
• ADCT-701: ADC Therapeutics
ADCT-701 is an ADC composed of a humanized IgG1 antibody against human DLK-1, site-specifically conjugated using Glycoconnect technology to PL1601, which contains a valine-alanine cleavable linker and the PBD dimer cytotoxin SG3199. In vitro, ADCT-701 demonstrated potent cytotoxicity in a panel of human cancer cell lines of different origin and levels of DLK-1, while its potency was strongly reduced in DLK-1-negative cell lines. In vivo, ADCT-701 showed potent anti-tumor activity in the DLK1-expressing neuroblastoma-derived SK-N-FI xenograft in which a single dose of ADCT-701 at 0.5 or 1 mg/kg showed dose-dependent anti-tumor activity compared to the vehicle- and isotype control ADC-treated mice. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Neuroendocrine Tumors.

Explore groundbreaking therapies and clinical trials in the Neuroendocrine Tumors Pipeline. Access DelveInsight's detailed report now! @ Neuroendocrine Tumors Treatment Drugs- https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Neuroendocrine Tumors Companies
Amgen, Eli Lilly and Company, GlaxoSmithKline, Hutchison Medipharma Limited, Ipsen, Seneca Therapeutics, Crinetics Pharmaceuticals, ADC Therapeutics, BeiGene, Camurus, EpicentRx, RayzeBio, Inc., Shenzhen Chipscreen Biosciences Co., Ltd., Vyriad, Inc. and others.

Neuroendocrine Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Neuroendocrine Tumors Products have been categorized under various Molecule types such as
• Monoclonal antibody
• Small molecule
• Peptide

Unveil the future of Neuroendocrine Tumors Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Neuroendocrine Tumors Market Drivers and Barriers- https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Neuroendocrine Tumors Pipeline Report
• Coverage- Global
• Neuroendocrine Tumors Companies- Amgen, Eli Lilly and Company, GlaxoSmithKline, Hutchison Medipharma Limited, Ipsen, Seneca Therapeutics, Crinetics Pharmaceuticals, ADC Therapeutics, BeiGene, Camurus, EpicentRx, RayzeBio, Inc., Shenzhen Chipscreen Biosciences Co., Ltd., Vyriad, Inc. and others.
• Neuroendocrine Tumors Therapies- Ipilimumab, Nivolumab, Pembrolizumab, Niraparib, Apalutamide, Selpercatinib, Cabozantinib, Vandetanib, and others.
• Neuroendocrine Tumors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Neuroendocrine Tumors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Neuroendocrine Tumors Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Neuroendocrine Tumors Companies, Key Products and Unmet Needs- https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Neuroendocrine Tumors: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Neuroendocrine Tumors- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. RYZ101: RayzeBio, Inc.
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. SVV-001: Seneca Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ADCT-701: ADC Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Product Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Neuroendocrine Tumors Key Companies
21. Neuroendocrine Tumors Key Products
22. Neuroendocrine Tumors- Unmet Needs
23. Neuroendocrine Tumors- Market Drivers and Barriers
24. Neuroendocrine Tumors- Future Perspectives and Conclusion
25. Neuroendocrine Tumors Analyst Views
26. Neuroendocrine Tumors Key Companies
27. Appendix

List of Top Selling Market Research Reports in 2024

Surgical Energy Generators Market- https://www.delveinsight.com/report-store/surgical-energy-generators-market
Surgical Sealant Tissue Patch Market- https://www.delveinsight.com/report-store/surgical-sealant-tissue-patch-market
Surgical Stapling Devices Market- https://www.delveinsight.com/report-store/surgical-stapling-devices-market
Vital Sign Monitoring Devices Market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
Syphilis Market- https://www.delveinsight.com/report-store/syphilis-market
Vitreoretinal Surgery Devices Market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
Pelvic Organ Prolapse Market- https://www.delveinsight.com/report-store/pelvic-organ-prolapse-market
Scoliosis Market- https://www.delveinsight.com/report-store/scoliosis-market
SGLT2 Inhibitors Market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
Urinary Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
Carcinoid Syndrome Market- https://www.delveinsight.com/report-store/carcinoid-syndrome-market
Cardiac Monitoring Devices Market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
Varicose Vein Treatment Devices Market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
Bone Growth Stimulators Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Skin Neoplasms Market- https://www.delveinsight.com/report-store/skin-neoplasms-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Novel Drug Delivery Devices Market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Lymphedema Market- https://www.delveinsight.com/report-store/lymphedema-market
Artificial Disc Market- https://www.delveinsight.com/report-store/artificial-disc-market
Exocrine Pancreatic Insufficiency Market- https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epi-market
Fabry Disease Market- https://www.delveinsight.com/report-store/fabry-disease-market
Overactive Bladder Market- https://www.delveinsight.com/report-store/overactive-bladder-oab-market
Total Knee Arthroplasty Market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Hip Replacement Devices Market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Lactose Intolerance Market- https://www.delveinsight.com/report-store/lactose-intolerance-market
HDAC Inhibitors Market- https://www.delveinsight.com/report-store/hdac-inhibitors-market
Ventral Hernia Market- https://www.delveinsight.com/report-store/ventral-hernia-market
Facial Lines Market- https://www.delveinsight.com/report-store/facial-lines-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Microscopy Device Market- https://www.delveinsight.com/report-store/microscopy-device-market

About DelveInsight

DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas

This release was published on openPR.